GLPwatch

GLP-1/Exendin-4 induces β-cell proliferation via the epidermal growth factor receptor.

Sci Rep · 2017

Last updated 2026-05-28

In a study using mice, the GLP-1 drug exendin-4 increased the growth of insulin-producing cells in the pancreas by activating a pathway involving the epidermal growth factor receptor (EGFR). This suggests that EGFR may play a role in how exendin-4 helps control blood sugar levels by boosting the number of these cells.

AI summary of the abstract below.

JournalSci Rep, 2017
Citations30
Relative citation ratio1.11
NIH percentile54
Molecules
Conditions studied Type 2 Diabetes

Abstract

Exendin-4 is a long acting glucagon-like peptide 1 (GLP-1) analogue that is an agonist for the GLP-1 receptor, a G-protein coupled receptor (GPCR). Exendin-4 is used to clinically improve glucose tolerance in diabetic patients due to its ability to enhance insulin secretion. In rodents, and possibly in humans, exendin-4 can stimulate β-cell proliferation. The exact mechanism of action to induce β-cell proliferation is not well understood. Here, using a β-cell specific epidermal growth factor receptor (EGFR) null mouse, we show that exendin-4 induced an increase in proliferation and β-cell mass through EGFR. Thus, our study sheds light on the role of EGFR signaling in the effects of exendin-4 on the control of blood glucose metabolism and β-cell mass.

Verbatim abstract via PubMed 28831150 ↗